The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
Proposed combination enhances Pfizer’s position as a leading company in oncology
Twelve hospitals across India will be part of the network which will support the trial in India
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
This clearance allows the company to initiate a clinical trial for patients with an ileal pouch-anal anastomosis
Subscribe To Our Newsletter & Stay Updated
